Targeted drug shows promise for Hard-to-Treat bladder cancers
NCT ID NCT03375307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called olaparib in 60 people with advanced bladder or related cancers that have specific DNA repair defects. Olaparib blocks a protein that cancer cells need to fix their DNA, which may stop the cancer from growing. The goal is to see if the drug can shrink tumors and help people live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
NCI - Center for Cancer Research
Bethesda, Maryland, 20892, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego Health System - Encinitas
Encinitas, California, 92024, United States
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New strategy aims to eliminate residual bladder cancer after drug combo
- New hope for bladder cancer patients who Can't take chemo
- Experimental triple therapy for advanced cancers shows early promise but trial halted